297 related articles for article (PubMed ID: 29757040)
1. Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.
Grewal S; Ramsey S; Balu S; Carlson JJ
Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):447-454. PubMed ID: 29757040
[TBL] [Abstract][Full Text] [Related]
2. Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective.
Trautman H; Szabo E; James E; Tang B
J Manag Care Spec Pharm; 2019 Jan; 25(1):94-101. PubMed ID: 30084301
[TBL] [Abstract][Full Text] [Related]
3. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
Chen B; Nagai S; Armitage JO; Witherspoon B; Nabhan C; Godwin AC; Yang YT; Kommalapati A; Tella SH; DeAngelis C; Raisch DW; Sartor O; Hrushesky WJ; Ray PS; Yarnold PR; Love BL; Norris LB; Knopf K; Bobolts L; Riente J; Luminari S; Kane RC; Hoque S; Bennett CL
Oncologist; 2019 Apr; 24(4):537-548. PubMed ID: 30842244
[TBL] [Abstract][Full Text] [Related]
4. Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim.
McBride A; Wang W; Campbell K; Balu S; MacDonald K; Abraham I
J Med Econ; 2020 Aug; 23(8):856-863. PubMed ID: 32323582
[No Abstract] [Full Text] [Related]
5. Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim.
Socal MP; Anderson KE; Sen A; Bai G; Anderson GF
Value Health; 2020 Apr; 23(4):481-486. PubMed ID: 32327165
[TBL] [Abstract][Full Text] [Related]
6. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.
McBride A; Campbell K; Bikkina M; MacDonald K; Abraham I; Balu S
J Med Econ; 2017 Oct; 20(10):1083-1093. PubMed ID: 28722494
[TBL] [Abstract][Full Text] [Related]
7. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
Mansell K; Bhimji H; Eurich D; Mansell H
BMC Health Serv Res; 2019 Nov; 19(1):827. PubMed ID: 31718624
[TBL] [Abstract][Full Text] [Related]
8. Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018.
Qian J
J Manag Care Spec Pharm; 2021 May; 27(5):660-666. PubMed ID: 33908273
[No Abstract] [Full Text] [Related]
9. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz.
McBride A; Balu S; Campbell K; Bikkina M; MacDonald K; Abraham I
Future Oncol; 2017 Oct; 13(25):2285-2295. PubMed ID: 28870106
[TBL] [Abstract][Full Text] [Related]
10. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
Sun D; Andayani TM; Altyar A; MacDonald K; Abraham I
Clin Ther; 2015 Apr; 37(4):842-57. PubMed ID: 25704107
[TBL] [Abstract][Full Text] [Related]
11. Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products.
Mouslim MC; Trujillo AJ; Alexander GC; Segal JB
Value Health; 2020 Dec; 23(12):1599-1605. PubMed ID: 33248515
[TBL] [Abstract][Full Text] [Related]
12. Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer.
MacDonald K; Alrawashdh N; McBride A; Abraham I
Future Oncol; 2021 Nov; 17(33):4561-4570. PubMed ID: 34382416
[TBL] [Abstract][Full Text] [Related]
13. Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives.
Baker JF; Leonard CE; Lo Re V; Weisman MH; George MD; Kay J
Arthritis Rheumatol; 2020 Jul; 72(7):1067-1071. PubMed ID: 32253823
[TBL] [Abstract][Full Text] [Related]
14. Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia.
Cesarec A; Likić R
Appl Health Econ Health Policy; 2017 Apr; 15(2):277-286. PubMed ID: 27730538
[TBL] [Abstract][Full Text] [Related]
15. Conversion from Filgrastim to Tbo-filgrastim: Experience of a Large Health Care System.
Agboola F; Reddy P
J Manag Care Spec Pharm; 2017 Dec; 23(12):1214-1218. PubMed ID: 29172977
[TBL] [Abstract][Full Text] [Related]
16. Expanded access to anticancer treatments from conversion to biosimilar pegfilgrastim-cbqv in US breast cancer patients.
McBride A; Alrawashdh N; MacDonald K; Abraham I
Future Oncol; 2022 Jan; 18(3):363-373. PubMed ID: 34747185
[TBL] [Abstract][Full Text] [Related]
17. Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage.
Karaca-Mandic P; Chang J; Go R; Schondelmeyer S; Weisdorf D; Jeffery MM
Health Aff (Millwood); 2019 Nov; 38(11):1887-1892. PubMed ID: 31682491
[TBL] [Abstract][Full Text] [Related]
18. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries.
Lee SM; Jung JH; Suh D; Jung YS; Yoo SL; Kim DW; Kim JA; Suh DC
BioDrugs; 2019 Aug; 33(4):423-436. PubMed ID: 31201616
[TBL] [Abstract][Full Text] [Related]
19. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis.
Aladul MI; Fitzpatrick RW; Chapman SR
Res Social Adm Pharm; 2019 Mar; 15(3):310-317. PubMed ID: 29807834
[TBL] [Abstract][Full Text] [Related]
20. Greater uptake, an alternative reimbursement methodology needed to realize cost-saving potential of oncology biosimilars in the United States.
Yang J; Carioto J; Pyenson B; Smith R; Jacobson N; Pittinger S; Shelbaya A
J Manag Care Spec Pharm; 2021 Dec; 27(12):1642-1651. PubMed ID: 34677089
[No Abstract] [Full Text] [Related]
[Next] [New Search]
